Clinical Trials Directory

Trials / Completed

CompletedNCT04173364

Interscalene Block and Dysfunction Diaphragmatic

Interscalene Block and Dysfunction Diaphragmatic: Effect of Low Volume of Ropivacaine 0,1%. A Randomised, Controlled Trial

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
60 (actual)
Sponsor
University Hospital, Lille · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The study seeks to show that interscalene injection of a small volume (\<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB.

Detailed description

It's a prospective monocentric randomized controlled clinical trial in 2 parallel groups in double blind. the study concerns patients undergoing arthroscopic shoulder surgery with ISB. The study seeks to show that interscalene injection of a small volume (\<8ml) of ropivacaine at a low concentration (0.1%) reduces the frequency of hemi-diaphragmatic paresis compared to low volume injection at the standard concentration (0.5%) in patients undergoing arthroscopic shoulder surgery with ISB. Randomization in one of the two arms: * Experimental group: \<8ml ropivacaine 0.1%. * Control group: \<8mL of ropivacaine 0.5%. Evaluation of diaphragmatic stroke by ultrasound and ventilatory function by spirometry and snip test before performing the ISB, then after installation of the ISB. Performing the surgical procedure under general anesthesia assessment of postoperative analgesia and patient satisfaction during the following 48 hours.

Conditions

Interventions

TypeNameDescription
DRUGRopivacaine 0.5% Injectable SolutionInjectable solution of ropivacaine 0.5%
DRUGRopivacaine 0.1% Injectable SolutionDilution of ropivacaine to the concentration of 0.1%

Timeline

Start date
2019-10-29
Primary completion
2020-09-21
Completion
2020-09-21
First posted
2019-11-21
Last updated
2022-06-21

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04173364. Inclusion in this directory is not an endorsement.